Hetrombopag

Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia. It is a non-peptide small‐molecule thrombopoietin receptor agonist. In China, it is approved for second-line treatment for primary immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA) in adults.
Wikipedia contributors, "Hetrombopag", Wikipedia, revision 1330286454, retrieved 20 November 2026, source, CC BY-SA 4.0.